

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
4100.003200Serial No.  
10/625,839Applicants  
George J. Brewer, Sofia D. Merajver and Dimitri  
CoucouvannisFiling Date:  
July 23, 2002Group:  
1614U.S. Patent Documents  
See Page 1 and 2Foreign Patent Documents  
See Page 2Other Art  
See Pages 2 - 14

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
2-F	A1	4,762,705	08/09/88	Rubin	424	85	
	A2	5,057,302	10/15/91	Johnson <i>et al.</i>	424	1.1	
	A3	5,100,885	03/31/92	Abrams <i>et al.</i>	514	184	
	A4	5,169,858	12/08/92	Rubin	514	365	
	A5	5,385,933	01/31/95	Rabinovitz <i>et al.</i>	514	499	
	A6	5,563,132	10/08/96	Bodaness	514	185	
	A7	5,697,902	12/16/97	Goldenberg	604	49	
	A8	5,565,491	10/15/96	Schieven	514	492	
	A9	5,512,559	04/30/96	Skalkos <i>et al.</i>	514	185	
	A10	5,443,816	08/22/95	Zamora <i>et al.</i>	424	1.69	
	A11	5,391,547	02/21/95	Cole <i>et al.</i>	514	184	
	A12	4,952,607	08/28/90	Sorenson <i>et al.</i>	514	589	
	A13	4,766,226	08/23/88	Hill <i>et al.</i>	556	18	
	A14	4,678,667	07/07/87	Meares <i>et al.</i>	424	85	
	A15	RE 35,458	02/18/97	Azuara	556	116	
	A16	5,112,598	05/12/92	Biesalski	424	46	
	A17	5,527,533	06/18/96	Tso <i>et al.</i>	424	422	
	A18	5,556,611	09/17/96	Biesalski	424	46	
	A19	5,583,153	12/10/96	Brahn	514	449	
2-F	A20	5,970,974	10/26/99	van der Linden <i>et al.</i>	128	200.16	

EXAMINER:

DATE CONSIDERED:

7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
2f	A21	5,954,047	09/21/99	Armer <i>et al.</i>	128	200.23	
	A22	5,950,619	09/14/99	van der Linden <i>et al.</i>	128	200.16	
	A23	5,698,155	12/16/97	Grosswald <i>et al.</i>	264	402	
	A24	5,639,725	06/17/97	O'Reilly <i>et al.</i>	514	12	
	A25	4,765,539	08/23/88	Noakes <i>et al.</i>	239	3	
	A26	3,916,899	11/04/75	Theeuwes <i>et al.</i>	128	260	
	A27	3,845,770	11/05/74	Theeuwes <i>et al.</i>	128	260	
	A28	4,604,278	08/05/86	Reilly <i>et al.</i>	423	517	
	A29	4,343,746	08/10/82	Anglin <i>et al.</i>	556	57	
2f	A30	2,909,541	10/20/59	Hugel	260	429	
2f	A31	6,703,050	03/09/04	Brewer <i>et al.</i>	424	641	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
2f	B1	EP 1 107 795 B1	Nov. 27, 2002	EP			
	B2	EP 1 234 585 A2	Aug. 28, 2002	EP			
	B3	WO 00/13712	Mar. 16, 2000	PCT			
2f	B4	WO 2004/009072	Jan. 29, 2004	PCT			

EXAMINER:

Zahid Fay

DATE CONSIDERED:

7/17/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2-f	C1	Allen and Solomons, "Normal Intestinal Mechanisms in the Absorption of Copper," In: Absorption and Malabsorption of Mineral Nutrients, Solomons and Rosenberg, Eds., Alan R. Liss, Inc., New York, 12:199-229, 1984.
	C2	Alpem-Elran and Brem, "Angiogenesis in Human Brain Tumors: Inhibition by Copper Depletion," <i>Neurological Surgery</i> , pp. 498-500, publication date unknown.
	C3	Brem <i>et al.</i> , "Anticopper Treatment Inhibits Pseudopodial Protrusion and the Invasive Spread of 9L Gliosarcoma Cells in the Rat Brain," <i>Neurosurgery</i> , 26:391-396, 1990.
	C4	Brem <i>et al.</i> , "Inhibition of Angiogenesis and Tumor Growth in the Brain. Suppression of Endothelial Cell Turnover by Penicillamine and the Depletion of Copper, an Angiogenic Cofactor," <i>Am. J. Pathol.</i> , 137(5):1121-1142, 1990.
	C5	Brem <i>et al.</i> , "Tetrathiomolybdate, A Chelator of Copper, Reduces Intracerebral Peritumoral Edema in Rats," <i>Proc. Amer. Assoc. Cancer Res.</i> , 33:76, Abstract 455, 1992.
	C6	Bremner <i>et al.</i> , "Copper Metabolism in Rats Given di-or trithiomolybdates," <i>J. Inorg. Biochem.</i> , 16: 109, 1982.
	C7	Brewer and Yuzbasiyan-Gurkan, "Wilson Disease," <i>Medicine</i> , 71(3):139-164, 1992.
	C8	Brewer and Yuzbasiyan-Gurkan, "Wilson's Disease," In: Textbook of Clinical Neuropharmacology and Therapeutics, 2nd Edition, Klawans <i>et al.</i> , Eds., Raven Press, New York, pp. 191-205, 1992.
	C9	Brewer and Yuzbasiyan-Gurkan, "Wilson's Disease: An Update, with Emphasis on New Approaches to Treatment," <i>Dig. Dis.</i> , 7(4):178-193, 1989.
	C10	Brewer, "Interactions of Zinc and Molybdenum With Copper in Therapy of Wilson's Disease," <i>Nutr.</i> , 11(1 Suppl):114-116, 1995.
	C11	Brewer, "Practical Recommendations and New Therapies for Wilson's Disease," <i>Drugs</i> , 50(2):240-249, 1995.
	C12	Brewer, "Thiomolybdates in the Treatment of Wilson's Disease," <i>Arch. Neurol.</i> , 49:132-133, 1992.
	C13	Brewer, "Zinc in the Treatment of Wilson's Disease," <i>Nutrition and the MD.</i> 19(12), 1993.
	C14	Brewer <i>et al.</i> , "Treatment of Wilson's disease with Ammonium Tetrathiomolybdate. I Initial Therapy in 17 Neurologically Affected Patients," <i>Arch. Neurol.</i> , 51(6):545-554, 1994.
2-f	C15	Brewer <i>et al.</i> , "Use of Zinc Acetate to Treat Copper Toxicosis in Dogs," <i>JAVMA</i> , 201:564-568, 1992.

EXAMINER:



DATE CONSIDERED:

7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2. f	C16	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc XIII: Therapy with Zinc in Presymptomatic Patients from the Time of Diagnosis," <i>J. Lab. Clin. Med.</i> , 123:849-858, 1994.
	C17	Brewer <i>et al.</i> , "Initial therapy of Wilson's Disease Patients with Tetrathiomolybdate," <i>Arch. Neurol.</i> , 48(1):42-47, 1991.
	C18	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc III. Prevention of Reaccumulation of Hepatic Copper," <i>J. Lab. Clin. Med.</i> , 109:526-531, 1987.
	C19	Brewer <i>et al.</i> , "Oral Zinc Therapy for Wilson's Disease," <i>Annals. Int. Med.</i> , 99:314-320, 1983.
	C20	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc: IV. Efficacy Monitoring Using Urine and Plasma Copper," <i>Proc. Soc. Exper. Biol. Med.</i> , 184:446-455, 1987.
	C21	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Ammonium Tetrathiomolybdate II. Initial Therapy in 33 Neurologically Affected Patients and Follow-up on Zinc Therapy," <i>Arch. Neurol.</i> , 53:1017-1025, 1996.
	C22	Brewer <i>et al.</i> , "The Use of <sup>64</sup> Copper Measurements to Diagnose Canine Copper Toxicosis," <i>J. Vet. Int. Med.</i> , 6:41-43, 1992.
	C23	Brewer <i>et al.</i> , "Worsening of Neurological Syndrome Upon Initial Treatment of Wilson's Disease Patients with Penicillamine," <i>Arch. Neurol.</i> , 44:490-493, 1987.
	C24	Brewer <i>et al.</i> , "Development of Neurologic Symptoms in a Patient with Asymptomatic Wilson's Disease Treated with Penicillamine," <i>Arch. Neurol.</i> , 51:304-305, 1994.
	C25	Brewer <i>et al.</i> , "Zinc Therapy of Wilson's Disease VIII. Dose Response Studies," <i>J. Trace Elem. Exp. Med.</i> , 3:227-234, 1990.
	C26	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc: IX. Response of Serum Lipids," <i>J. Lab. Clin. Med.</i> , 118:466-470, 1991.
	C27	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc XI. Interaction with Other Anticopper Agents," <i>J. Amer. Coll. Nut.</i> , 12(1):26-30, 1993.
	C28	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc XII. Dose Regimen Requirements," <i>Amer. J. Med Sci.</i> , 305(4):199-202, 1993.
2. f	C29	Brewer <i>et al.</i> , "Molecular Genetics and Zinc-Copper Interactions in Human Wilson's Disease and Canine Copper Toxicosis," In: Essential and Toxic Trace Elements in Human Health and Disease: An Update, Prasad, Ed., Allan R. Liss, New York, PCBR 380:129-145, 1993.

EXAMINER:

Zuhair Fay

DATE CONSIDERED:


7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2-F	C30	Brewer <i>et al.</i> , "Treatment of Wilson's Disease with Zinc VI. Initial Treatment Studies," <i>J. Lab. Clin. Med.</i> , 114: 633-638, 1989.
	C31	Brewer <i>et al.</i> , "Treatment of Wilson's Disease," <i>Sem. Neural.</i> , 7:209-220, 1987.
	C32	Coucouvanis <i>et al.</i> , "An Inorganic Functional Group Approach to the Systematic Synthesis and Reactivity Studies of Binuclear Mo/S and Mo/S/O Complexes," <i>Polyhedron</i> , 8(13/14):1705-1716, 1989.
	C33	Coucouvanis <i>et al.</i> , "Dinuclear Fe-Mo-S Complexes Containing the FeS <sub>2</sub> Mo Core. Syntheses, Ground-State Electronic Structures, and Crystal and Molecular Structures of the [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [C <sub>6</sub> H <sub>5</sub> S] <sub>2</sub> FeS <sub>2</sub> MoS <sub>2</sub> ], [(C <sub>2</sub> H <sub>5</sub> ) <sub>4</sub> N] <sub>2</sub> [(C <sub>6</sub> H <sub>5</sub> S) <sub>2</sub> FeS <sub>2</sub> WS <sub>2</sub> ], and [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [(S) <sub>2</sub> FeS <sub>2</sub> MS <sub>2</sub> ] (M = Mo, W) Complexes," <i>Inorg. Chem.</i> , 22:293-308, 1983.
	C34	Coucouvanis <i>et al.</i> , "Heterodinuclear Di-μ-Sulfido Bridged Dimers Containing Iron and Molybdenum or Tungsten. Structures of (PhP) <sub>2</sub> (FeMS <sub>2</sub> ) Complexes (M = Mo, W)," <i>J. Am. Chem. Soc.</i> , 102:1730-1732, 1980.
	C35	Coucouvanis <i>et al.</i> , "Successful Isolation of a Reduced Tetrathiometalate Complex. Synthesis and Structural Characterization of the [(MoS <sub>4</sub> ) <sub>2</sub> Fe] <sup>3-</sup> Trianion," <i>J. Am. Chem. Soc.</i> , 102:6644-6646, 1980.
	C36	Coucouvanis <i>et al.</i> , "Synthesis and Structural Characterization of [(No) <sub>2</sub> FeS <sub>2</sub> MoS <sub>2</sub> ] <sup>2-</sup> A Dinitrosyl Complex Containing the FeS <sub>2</sub> MoS <sub>2</sub> Core," <i>Inorg. Chim. Acta</i> , 53:L135-L137, 1981.
	C37	Coucouvanis <i>et al.</i> , "Synthesis of Thiomolybdenyl Complexes with [Mo <sub>2</sub> (S) <sub>2</sub> (O) <sub>2</sub> ] <sup>2+</sup> Cores and Substitutionally Labile Ligands. Crystal and Molecular Structure of the [Mo <sub>2</sub> O <sub>2</sub> S <sub>4</sub> (DMF) <sub>3</sub> ] Complex," <i>Inorg. Chem.</i> , 27:3272-3273, 1988.
	C38	Coucouvanis <i>et al.</i> , "Trinuclear Fe-M-S Complexes Containing a Linear Fe-M-Fe Array and a Bridging S <sub>2</sub> MS <sub>2</sub> Unit. Electronic Structures and Crystal and Molecular Structures of the [(C <sub>6</sub> H <sub>5</sub> ) <sub>4</sub> P] <sub>2</sub> [Cl <sub>2</sub> FeS <sub>2</sub> MS <sub>2</sub> FeCl <sub>2</sub> ] (M = Mo, W) Complexes," <i>Inorg. Chem.</i> , 23:741-749, 1984.
	C39	Coucouvanis, "Fe-M-S Complexes Derived from MS <sub>4</sub> <sup>2-</sup> Anions (M = Mo, W) and Their Possible Relevance as Analogues for Structural Features in the Mo Site of Nitrogenase," <i>Acc. Chem. Res.</i> , 14:201-209, 1981.
2-F	C40	Coucouvanis, "Syntheses, Structures, and Reactions of Binary and Tertiary Thiomolybdate Complexes Containing the (O)Mo(S <sub>x</sub> ) and (S)Mo(S <sub>x</sub> ) Functional Groups (x = 1,2,4)," <i>Adv. Inorg. Chem.</i> , 45:1-73, 1998.

EXAMINER: 	DATE CONSIDERED: 7/7/06
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2-f	C41	Engleka and Maciag, "Inactivation of Human Fibroblast Growth Factor-1 (FGF- 1) Activity by Interaction with Copper Ions Involves FGF-1 Dimer Formation Induced by Copper-Catalyzed Oxidation," <i>J. Biol. Chem.</i> , 267:11307-11315, 1994.
	C42	Fell <i>et al.</i> , "Gut Pathology of Rats Dosed with Tetrathiomolybdate," <i>J. Corn. Pathol.</i> , 89:495, 1979.
	C43	Folkman, "Angiogenesis," <i>The Journal of Biological Chemistry</i> , 267(16):10931-1 0934, 1992.
	C44	Folkman and Klagsbrun, "Angiogenic Factors," <i>Science</i> , 23:442-447, 1987.
	C45	Folkman, "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease," <i>Nature Med.</i> , 1:27-31, 1995.
	C46	Folkman, "The Influence of Angiogenesis Research on Management of Patients with Breast Cancer," <i>Breast Cancer Res. Treat.</i> , 36(2):109-118, 1995.
	C47	Folkman, "Anti Angiogenic Therapy," In: <i>Cancer: Principles and Practice of Oncology</i> , Lippincott-Raven Publishers, pp. 3075-3085, 1997.
	C48	Gooneratne <i>et al.</i> , "An Investigation of the Effects of Inn Venous Administration of Thiomolybdate on Copper Metabolism in Chronic Cu-Poisoned Sheep," <i>Br. J. Nutr.</i> , 46:469, 1981.
	C49	Gooneratne <i>et al.</i> , "Intravenous Administration of Thiomolybdate for the Prevention and Treatment of Chronic Copper Poisoning in Sheep," <i>Br. J. Nutr.</i> , 46:457, 1981.
	C50	Gross <i>et al.</i> , "Inhibition of Basic Fibroblast Growth Factor-Induced Angiogenesis and Glioma Tumor Growth In Vivo in Copper Depleted Rats," <i>Proc. Amer. Assoc. Cancer Res.</i> , 32:57, Abstract 338, 1991.
	C51	Gullino, "Considerations on the Mechanism of the Angiogenic Response," <i>Anticancer Res.</i> , 6(2):153-158, 1986.
	C52	Hadjikyriacou and Coucouvanis, "New Members of the $[\text{Mo}_2(\text{S})_n(\text{S}_2)_{6-n}]^{2-}$ Series. Synthesis, Structural Characterization, and Properties of the $[\text{Mo}_2\text{S}_9]^{2-}$ , $[\text{Mo}_2\text{S}_7]^{2-}$ and $[\text{Mo}_2\text{S}_6]^{2-}$ Thioanions," <i>Inorg. Chem.</i> , 26:2400-2408, 1987.
	C53	Hill <i>et al.</i> , "Treatment of Wilson's Disease with Zinc II. Validation of Oral $^{64}\text{Cu}$ Copper Uptake with Copper Balance," <i>Am. J. Med. Sci.</i> , 12:344, 1986.
2-f	C54	Hill <i>et al.</i> , "Treatment of Wilson's Disease with Zinc, I: Oral Zinc Therapy Regimens," <i>Hepatology</i> , 7:522-528, 1987.

EXAMINER: <i>Zahid Fy</i>	DATE CONSIDERED: <i>7/7/06</i>
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2cf	C55	Hourani and Demopoulos, "Inhibition of S-91 Mouse Melanoma Metastases and Growth by D-Penicillamine," <i>Laboratory Investigation</i> , 21(5):434-438, 1969.
	C56	Kanatzidis and Coucouvanis, "Structure of Bis(tetraethylammonium) Tetrathiomolybdate(VI), $2C_8H_{20}N^+MoS_4^{2-}$ ," <i>Acta Cryst.</i> , C39:835-838, 1983.
	C57	Lee <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc VII. Protection of the Liver for Copper Toxicity by Zinc Induced Metallothionein in a Rat Model," <i>J. Lab. Clin. Med.</i> , 114:639-645, 1989.
	C58	Marshall <i>et al.</i> , "Phase I Trial of Orally Administered Pentosan Polysulfate in Patients with Advanced Cancer," <i>Clin. Cancer Res.</i> , 3:2347-2354, 1997.
	C59	Merajver <i>et al.</i> , "Copper Depletion as an Anti-Angiogenic Strategy in HER2-neu Transgenic Mice," Proceedings of Special AACR Conference on Angiogenesis and Cancer, Abstract #B-II, January 22-24, 1998.
	C60	Merajver, "Phase I Study of Tetrathiomolybdate in Metastatic Cancer," NIH Grant No. 5R03CA77122-02.
	C61	Mills <i>et al.</i> , "Effects of Molybdate, Sulfide, and Tetrathiomolybdate on Copper Metabolism in Rats," <i>J. Inorg. Biochem.</i> , 14:189, 1981.
	C62	Mills <i>et al.</i> , "Copper and Molybdenum Absorption by Rats Given Ammonium Tetrathiomolybdate," <i>J. Inorg. Biochem.</i> , 14: 163, 1981.
	C63	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea," <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C64	Patstone and Maher, "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271 :3343-3346, 1996.
	C65	Raju <i>et al.</i> , Ceruloplasmin, Copper Ions, and Angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:1183-1188, 1982.
	C66	Schapira and Schapira, "Use of Ceruloplasmin Levels to Monitor Response to Therapy and Predict Recurrence of Breast Cancer," <i>Breast Cancer Res. Treat.</i> , 3:223-224, 1983.
	C67	Schuschke <i>et al.</i> , "Short-Term Dietary Copper Deficiency does not Inhibit Angiogenesis in Tumours Implanted in Striated Muscle," <i>Br. J. Cancer</i> , 66:1059-1064, 1992.
2cf	C68	Shing, "Heparin-Copper Biaffinity Chromatography of Fibroblast Growth Factors," <i>J. Biol. Chem.</i> , 263:9059-9062, 1988.

EXAMINER: <i>2010/07/16</i>	DATE CONSIDERED: <i>7/17/06</i>
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2.F	C69	Teo <i>et al.</i> , "Mo, W, and Fe EXAFS of the $[Cl_2FeS_2MS_2FeCl_2]^{2-}$ (M = Mo, W) Dianions. A Comparison with the Mo EXAFS of Nitrogenase," <i>J. Am. Chem. Soc.</i> , 105:5767-5770, 1983.
	C70	Yoshida <i>et al.</i> , "Copper Chelation Inhibits Tumor Angiogenesis in the Experimental 9L Gliosarcoma Model," <i>Neurosurgery</i> , 37(2):287-292, 1995.
	C71	Yoshida <i>et al.</i> , "Suppression of 9L Gliosarcoma Growth by Copper Depletion with Copper-Deficient Diet and D-Penicillamine," <i>J. Neurooncol.</i> , 17(2):91-97, 1993.
	C72	Yuzbasiyan-Gurkan <i>et al.</i> , "Treatment of Wilson's Disease with Zinc V. Changes in Serum Levels of Lipase, Amylase and Alkaline Phosphatase in Wilson's Disease Patients," <i>J. Lab. Clin. Med.</i> , 114:520-526, 1989.
	C73	Yuzbasiyan-Gurkan <i>et al.</i> , "The Treatment of Wilson's Disease with Zinc X. Intestinal Metallothionein Induction," <i>J. Lab. Clin. Med.</i> , 120:380-386, 1992.
	C74	Zagzag, "The effects of Copper Depletion on Intracerebral Angiogenesis and Growth of Experimental Brain Tumors," <i>Dissertation Abstracts International</i> , 53(12B):6160, 1988.
	C75	Ziche <i>et al.</i> , "Role of Prostaglandin E1 and Copper in Angiogenesis," <i>J. Natl. Cancer Inst.</i> , 69:475-482, 1982.
	C76	Brem "Angiogenesis and Cancer Control: From Concept to Therapeutic Trail," <i>Cancer Control</i> , 6(5):436-458, 1999.
	C77	Brewer and Merajver, "Treatment of Metastatic Cancer with the Anticopper Antiangiogenic Drug Tetrathiomolybdate," <i>J. Invest. Med.</i> , 47(7):223A, 1999.
	C78	Brewer <i>et al.</i> , "Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study," <i>Clin. Canc. Res.</i> , 6(1):1-10, 2000.
	C79	International Search Report dated July 4, 2000 (PCT/US99/20374; 4100.001010).
	C80	Merajver, "A Phase I study of Oral Tetrathiomolybdate (TM) as a Decoppering and Anti-Angiogenesis Agent for Metastatic Cancer," From the Internet at website <a href="http://www.cancer.med.umich.edu/cgi-bin/protocol/9708_701">http://www.cancer.med.umich.edu/cgi-bin/protocol/9708_701</a> , 1998.
2.F	C81	Sergeant and Johnson, "Iron and Copper Requirements for Proliferation and Differentiation of a Human Promyelocytic Leukemia Cell Line (HL-60)," <i>J. Cell. Physiol.</i> , 163:477-485, 1995.

EXAMINER:

Zalutsky F

DATE CONSIDERED:

7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2-f	C82	Shah <i>et al.</i> , "Circular Dichroism of Carbohydrate-Molybdate Complexes," <i>Stud. Nat. Prod. Chem.</i> , 15:423-438, 1995.
2-f	C83	Benjamin <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
	C84	Borgstrom <i>et al.</i> , "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>In Vivo</i> ," <i>The Prostate</i> , 35:1-10, 1998.
	C85	Jeannin <i>et al.</i> , "Molecular Architecture of Copper(I) Thiometallate Complexes. Examples of a Cubane with an Extra Face, (NPr <sub>4</sub> ) <sub>3</sub> [MS <sub>4</sub> Cu <sub>4</sub> Cl <sub>3</sub> ]," <i>Inorganic. Chimica. Acta.</i> , 198-200:493-500, 1992.
	C86	Malavé <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngenic Mice," <i>J. Natl. Cancer Inst.</i> , 62(1):83-88, 1979.
	C87	Passaniti <i>et al.</i> , "Methods in Laboratory Investigation," <i>Laboratory Investigation</i> , 67(4):519-528, 1992.
	C88	Sécheresse <i>et al.</i> , "Heterobimetallic Aggregates of Copper(I) with Thio-tungstate and -molybdate. Cation Effect in Aggregation of Ms <sub>4</sub> Cu <sub>4</sub> Cl <sub>3</sub> Units, a Crystallographic Study," <i>J. Chem. Soc. Dalton Trans.</i> , 11:2875-2881, 1991.
	C89	Sugiura <i>et al.</i> , "Studies in a Tumor Spectrum," <i>Cancer Research</i> , 15:38-51, 1955.
	C90	Takai <i>et al.</i> , "Preparation, Structure and Properties of Mixed-Metal Trinuclear Complex: (Pr <sub>4</sub> N) <sub>2</sub> [MoO(WS <sub>4</sub> ) <sub>2</sub> ]," <i>Chemistry Letters</i> , 8:645-646, 1996.
	C91	Bajou <i>et al.</i> , "Absence of Host Plasminogen Activator Inhibitor I Prevents Cancer Invasion and Vascularization," <i>Nat. Med.</i> , 4:923-928, 1998.
	C92	Bamba <i>et al.</i> , "Release Mechanisms in Gel Forming Sustained Release Preparations," <i>Int. J. Pharm.</i> , 2:307, 1979.
	C93	Blood <i>et al.</i> , "Tumor Interactions With the Vasculature: Angiogenesis and Tumor Metastasis," <i>Biochim. Biophys. Acta.</i> , 1032:89-118, 1990.
2-f	C94	Brown, "Metal Toxicity and Therapeutic Intervention," <i>Biochem. Soc. Trans.</i> , 30:742- 745 2002.

EXAMINER:

Zachary Fay

DATE CONSIDERED:

7/17/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2.f	C95	Brown, "Copper and Prion Disease," <i>Brain Res. Bull.</i> , 55:165-173, 2001.
	C96	Carri <i>et al.</i> , "Copper-Dependent Oxidative Stress, Alteration of Signal Transduction and Neurodegeneration in Amyotrophic Lateral Sclerosis," <i>Funct. Neurol.</i> , 16:181-188, 2001.
	C97	Chakravarty <i>et al.</i> , "Serum Copper in Malignant Neoplasia with Special Reference to the Cervix Uteri," <i>J. Cancer Res. Clin. Oncol.</i> , 108: 312-315, 1984.
	C98	Chambers <i>et al.</i> , "Macrophage Colony-Stimulating Factor Mediates Invasion of Ovarian Cancer Cells Through Urokinase," <i>Cancer Research</i> , 55:1578-1585, 1995.
	C99	Chen <i>et al.</i> , "TNF-RI Signaling: A Beautiful Pathway," <i>Science</i> , 296:1634-1635, 2002.
	C100	Crowley <i>et al.</i> , "Prevention of Metastasis by Inhibition of the Urokinase Receptor," <i>Proc. Nat'l. Acad. Sci. USA</i> , 90:5021-5025, 1993.
	C101	During <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant; In vivo Characterization," <i>Ann. Neurol.</i> , 25:351-356, 1989.
	C102	Folkman, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," <i>Ann. Surg.</i> , 175: 409-416, 1972.
	C103	Folkman, "Angiogenesis Inhibitors Generated by Tumors," <i>Mol. Med.</i> , 1(2):120-122 1995.
	C104	Gnjec <i>et al.</i> , "Transition Metal Chelator Therapy - A potential Treatment For Alzheimer's Disease?" <i>Front Biosci.</i> , 16-23, 2002.
	C105	Goodson, "Medical Applications of Controlled Release" 2:115-138, 1984.
	C106	Gorelik <i>et al.</i> , "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," <i>J. Nat'l. Cancer Inst.</i> , 65: 1257-1264, 1980.
	C107	Gorelik, <i>et al.</i> , "Host's Immune State and Kinetics of Local Tumor Growth Control- Progression of Postoperative Lung Metastasis," <i>Rec. Results Cancer Res.</i> , 75:20-28, 1980.
	C108	Hanada <i>et al.</i> , "Regulation of Cytokine Signaling and Inflammation," <i>Cytokine Growth Factor Rev.</i> , 13: 413-421, 2002.
	C109	Hanahan <i>et al.</i> , "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):353-364, 1996.
2.f	C110	Hilgard <i>et al.</i> , "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," <i>Br. J. Cancer</i> , 35:78-86, 1977.

EXAMINER:

Zohar Fay

DATE CONSIDERED:

7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2-f	C111	Howard <i>et al.</i> , "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," <i>J. Neurosurg.</i> , 71:105-112, 1989.
1	C112	Isakov <i>et al.</i> , "An Immune Response Against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," <i>Invasion Metas.</i> , 2:12-32, 1982.
	C113	Kleinman <i>et al.</i> , "Basement Membrane Complexes with Biological Activity," <i>Biochem.</i> , 25: 312-318, 1986.
	C114	Koch <i>et al.</i> , "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis," <i>Science</i> , 258:1798-1801, 1992.
	C115	Kowalik-Jankowska <i>et al.</i> , "Possible Involvement of Copper (II) in Alzheimer Disease," <i>Environ. Health Perspect.</i> , 5:869-870, 2002.
	C116	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem.</i> , 23:61-126, 1983.
	C117	Langer, "New Methods of Drug Delivery," <i>Science</i> , 249:1527-1533, 1990.
	C118	Levy <i>et al.</i> , Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled- Release Diphosphonate," <i>Science</i> , 228:190-192, 1985.
	C119	Llanos <i>et al.</i> , "The Molecular Basis of Copper Homeostasis and Copper-Related Disorders," <i>DNA Cell Biol.</i> , 21:259-270, 2002.
	C120	Loskutoff <i>et al.</i> , "A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM," <i>Ann. N.Y. Acad. Sci.</i> , 902:272-282, 2000.
	C121	Malave <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," <i>J. Nat'l. Cancer Inst.</i> , 62:83-88, 1979.
	C122	Mandinov <i>et al.</i> , "Copper Chelation Represses the Vascular Response To Injury" <i>PNAS</i> , 100:6700-6705, 2003.
	C123	Maynard <i>et al.</i> , "Overexpression of Alzheimer's Disease Amyloid- $\beta$ Opposes the Age-Dependent Elevations of Brain Copper and Iron," <i>J. Biol. Chem.</i> , 277(47):44670-44676, 2002.
2-f	C124	Millauer <i>et al.</i> , "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>In vivo</i> ," <i>Cancer Res.</i> , 56:1615-1620, 1996.

EXAMINER: <i>Zohar Fey</i>	DATE CONSIDERED: 7/17/06
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2f	C125	Min <i>et al.</i> , "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> , 56:2428-2433, 1996.
	C126	Miyake <i>et al.</i> , "Transforming Growth Factor- $\beta$ 1 Stimulates Contraction of Human Glioblastoma Cell-Mediated Collagen Lattice Through Enhanced $\alpha$ 2 Integrin Expression," <i>J. Neuropathol. Exp. Neurol.</i> , 59:18-28, 2000.
	C127	Nguyen <i>et al.</i> , "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," <i>Microvascular Res.</i> , 47:31-40, 1994.
	C128	Odedra <i>et al.</i> , "Low Molecular Weight Angiogenesis Factors," <i>Pharmac. Ther.</i> , 49:111-124, 1991.
	C129	Osawa <i>et al.</i> , "Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF-kB and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes," <i>Infect. Immun.</i> , 70:6294-6301, 2002.
	C130	Pan <i>et al.</i> , "Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis," <i>Cancer Res.</i> , 62: 4854-4859, 2002.
	C131	Parish <i>et al.</i> , "A Basement-Membrane Permeability Assay Which Correlates with the Metastatic Potential of Tumor Cells," <i>Int. J. Cancer</i> , 52:378-383, 1992.
	C132	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea" <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C133	Passaniti <i>et al.</i> , "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Lab. Invest.</i> , 67:519-528, 1992.
	C134	Patstone <i>et al.</i> , "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271(7):3343-3346, 1996.
	C135	Perry <i>et al.</i> , "The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders," <i>CNS Drugs</i> , 16:339-352, 2002.
	C136	Rabbani <i>et al.</i> , "Prevention of Prostate-Cancer Metastasis <i>In Vivo</i> By a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)," <i>Int. J. Cancer</i> , 63:840-845, 1995.
2-f	C137	Redman <i>et al.</i> , "Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer," <i>Clin. Cancer Res.</i> , 9:1666-1672, 1996.

EXAMINER:

Zuhair Fg

DATE CONSIDERED:


7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvanis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2cf	C138	Rupnick <i>et al.</i> , "Adipose Tissue Mass Can Be Regulated Through the Vasculature," <i>Proc. Natl. Acad. Sci.</i> , 99:10730-10735, 2002.
	C139	Saudek <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 321:574, 1989.
	C140	Schnaper <i>et al.</i> , "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> , 165:107-118, 1995.
	C141	Sefton, "Implantable Pumps," <i>CRC Crit. Rev. Biomed. Eng.</i> , 14(3):201-240, 1987.
	C142	Sen <i>et al.</i> , "Copper-Induced Vascular Endothelial Growth Factor Expression and Wound Healing," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:H1821-H1827, 2002.
	C143	Shockley <i>et al.</i> , "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," <i>Ann. N.Y. Acad. Sci.</i> , 617:367-382, 1991.
	C144	Strausak <i>et al.</i> , "Copper in Disorders with Neurological Symptoms: Alzheimer's, Menkes, and Wilson Diseases," <i>Brain Res. Bull.</i> , 55:175-185, 2001.
	C145	Talmadge <i>et al.</i> , "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," <i>J. Nat'l. Cancer Inst.</i> , 69:975-980, 1982
	C146	Thakur <i>et al.</i> , "Indium-111-Labeled Leukocytes for the Localization of Abscesses: Preparation, Analysis, Tissue Distribution, and Comparison with Gallium-67 Citrate in Dogs," <i>J. Lab. Clin. Med.</i> , 89:217-228, 1977.
	C147	Treat <i>et al.</i> , in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, 353-365, 1989.
	C148	Van Golen <i>et al.</i> , "Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma," <i>Neoplasia</i> , 4(5):373-379, 2002.
	C149	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Develop. Indus. Pharm.</i> , 26(7):695-708, 2000.
	C150	Verschoye <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> , 80, Suppl. 2, 96, 1999.
2cf	C151	Volpert <i>et al.</i> , "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," <i>J. Clin. Invest.</i> , 98:671-679, 1996.

EXAMINER: 	DATE CONSIDERED: 7/17/06
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4100.003200	Serial No. 10/625,839
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicants George J. Brewer, Sofia D. Merajver and Dimitri Coucouvannis	
		Filing Date: July 23, 2002	Group: 1614
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Pages 2 - 14	

### Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2cf	C152	Xing <i>et al.</i> , "Overexpression of Urokinase Receptor in Breast Cancer Cells Results in Increased Tumor Invasion, Growth and Metastasis," <i>Int. J. Cancer</i> , 67:423-429, 1996.
2cf	C153	International Search Report for PCT/US03/003210, mailed December 18, 2003 (4100.003210).
2cf	C154	International Search Report for PCT/US03/23031, mailed June 29, 2004

EXAMINER:



DATE CONSIDERED:

7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.  
4100.003200Serial No.  
10/625,839

List of Patents and Publications for Applicant's

Applicants

George J. Brewer, Sofia D. Merajver and Dimitri  
Coucovanis

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 23, 2002Group:  
1614U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See PageOther Art  
See Page

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
ZF	A32	5,639,757	June 17, 1997	Dow <i>et al.</i>	514	261	
	A33	5,712,291	Jan. 27, 1998	D'Amato	514	323	
	A34	5,753,230	May 19, 1998	Brooks <i>et al.</i>	424	158.1	
	A35	5,972,922	Oct. 26, 1999	Wilks <i>et al.</i>	514	178	
ZF	A36	2004/0009237 A1	Jan. 15, 2004	Brewer	424	617	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date, Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

*Zabur Fay*

DATE CONSIDERED:

7/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.